Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Imaging Tech Forum May Lead To Further FDA/CMS Collaboration

This article was originally published in The Gray Sheet

Executive Summary

The National Cancer Institute's Interagency Council on Biomedical Imaging in Oncology has had 36 requests for meetings with manufacturers and researchers since its inception in June 2000

You may also be interested in...



FDA Tags Academic Researcher To Probe Advisory Panel Conflicts Of Interest

A joint conflict-of-interest study by FDA and the University of Maryland will survey attendees at the agency's April Circulatory System Devices Advisory Panel and National Mammography Quality Assurance Advisory Committee meetings, according to the project's primary investigator

FDA Tags Academic Researcher To Probe Advisory Panel Conflicts Of Interest

A joint conflict-of-interest study by FDA and the University of Maryland will survey attendees at the agency's April Circulatory System Devices Advisory Panel and National Mammography Quality Assurance Advisory Committee meetings, according to the project's primary investigator

FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis

Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11

Related Content

UsernamePublicRestriction

Register

MT016034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel